Certolizumab pegol治疗斑块状银屑病三年疗效与安全性:CIMPACT随机3期试验结果
CIMPACT是3期随机对照试验,评估Certolizumab pegol(CZP)治疗中重度斑块状银屑病的3年结局。开放标签扩展期(第48-144周)中,继续200mg Q2W者PASI 75维持率达96.2%(第144周);从400mg减至200mg Q2W者PASI 75下降(第48周98.7%→第144周85.9%);安慰剂转200mg Q2W者从第48周60.4%升至第144周95.1%。未发现新的安全性信号。
要点
- 持续CZP 200mg Q2W治疗至第144周,PASI 75维持率96.2%。
- 第48周从400mg减至200mg Q2W者,PASI 75从98.7%降至85.9%。
- 安慰剂转200mg Q2W后PASI 75从60.4%升至95.1%,未发现新安全性信号。
核心结论
- CZP治疗中重度斑块状银屑病应答可持续三年,未发现新的安全性信号。
研究设计与样本
- CIMPACT(NCT02346240)为3期随机对照试验,成人按3:3:3:1随机分配至CZP 200mg Q2W、CZP 400mg Q2W、依那西普或安慰剂。
- 第16周PASI 75应答者重新随机维持治疗,非应答者进入开放标签逃逸臂CZP 400mg Q2W。
- 进入开放标签扩展期(第48-144周)者接受CZP 200mg Q2W,共261例。
主要发现
- 继续200mg Q2W治疗者PASI 75应答从第16周维持至第144周(第144周96.2%)。
- 第48周从双盲400mg减至200mg Q2W者PASI 75下降(第48周98.7%→第144周85.9%)。
- 第16-48周接受安慰剂者PASI 75下降(第48周60.4%),第48周转200mg Q2W后升至95.1%(第144周)。
- 初始随机至200mg和400mg Q2W的第16周PASI 75非应答者分别48例和36例进入逃逸臂,第144周PASI 75达标率分别为71.8%和78.2%。
临床怎么用
- 中重度斑块状银屑病长期维持治疗可考虑CZP 200mg Q2W,三年应答持久。
- 从400mg减至200mg Q2W需关注PASI 75应答下降,必要时评估剂量调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Certolizumab pegol (CZP) is an Fc-free, PEGylated anti-tumor necrosis factor biologic. OBJECTIVES: To report 3-year outcomes from the CIMPACT (NCT02346240) phase 3, CZP in moderate to severe plaque psoriasis, randomized controlled trial. METHODS: Adults were randomized 3:3:3:1 to CZP 200 mg every other week (Q2W), CZP 400 mg Q2W, etanercept biweekly or placebo. At Week 16, CZP- and etanercept-treated PASI 75 responders were re-randomized to CZP 200 mg Q2W, CZP 400 mg Q4W, CZP 400 mg Q2W or placebo for maintenance treatment; PASI 75 non-responders entered an open-label escape CZP 400 mg Q2W arm. Patients entering the open-label extension (OLE; Weeks 48-144) from blinded treatment received CZP 200 mg Q2W. RESULTS: Double-blinded results have been reported previously. 261 patients received 200 mg Q2W upon OLE entry. PASI 75 response was maintained in patients continuing 200 mg Q2W treatment through Weeks 16-144 (Week 144: 96.2%). In patients dosed down at Week 48 (double-blinded 400 mg to 200 mg Q2W), PASI 75 decreased (Week 48: 98.7%; Week 144: 85.9%). In patients who received placebo through Weeks 16-48, PASI 75 response decreased (Week 48: 60.4%), then increased following Week 48 switch to 200 mg Q2W (Week 144: 95.1%). 48 and 36 patients initially randomized to 200 and 400 mg Q2W, respectively, were Week 16 PASI 75 non-responders and entered the escape arm; at Week 144, 71.8% and 78.2% achieved PASI 75. No new safety signals were identified. CONCLUSIONS: Response to CZP was durable over three years; no new safety signals were identified.
引用
- Warren RB, Lebwohl M, Sofen H, et al. Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial. J Eur Acad Dermatol Venereol. 2021. PMID: 34192387. doi:10.1111/jdv.17486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。